LL37-rIb-AMP4 Hybrid Peptide as a Therapy for Systematic Infections of Acinetobacter baumannii, Pseudomonas aeruginosa, Vancomycin-resistant Enterococcus (VRE), and Methicillin-resistant Staphylococcus aureus (MRSA) cells in a mouse model.

Document Type : Original Research

Authors
1 Molecular and Medical Research Center, Arak University of Medical Sciences, Arak, Iran.
2 Department of Internal Medicine, School of Medicine, Amiralmomenin Hospital, Arak University of Medical Sciences, Arak, Iran.
Abstract
Aims: Antimicrobial peptides (AMPs) are beneficial compounds that could be used as a new and effective method to suppress microbes. Both Ib-AMP4 and LL37 are antimicrobial peptides with a wide range of antimicrobial activities. This research aimed to evaluate the antibacterial potential of LL37-rIb-AMP4 hybrid protein as an antimicrobial agent against pathogenic bacteria. Therefore, its antibacterial effects against Acinetobacter baumannii, Pseudomonas aeruginosa, vancomycin-resistant Enterococcus (VRE), and methicillin-resistant Staphylococcus aureus (MRSA) were investigated in vivo and in vitro.

Materials & Methods: In this study, antimicrobial peptides rIb-AMP4, LL37, and LL37-rIb-AMP4 were expressed, purified, and refolded, and their synergistic and antibacterial effects in combination with each other (LL37+rIb-AMP4) and as fusion proteins (LL37-rIb-AMP4) were tested against A. baumannii, P. aeruginosa, VRE, and MRSA cells in vitro (MIC, time kill, and SEM) and against P. aeruginosa and VRE cells in vivo.

Findings: LL37-rIb-AMP4 Protein with molecular weight= 28 KD was correctly produced and purified. Despite the lack of synergistic effects between LL37 and rIb-AMP4 peptides in vitro, the stability test results showed higher stability for LL37-rIb-AMP4 hybrid protein.

The findings of in vivo tests confirmed that all infected mice were improved with LL37-rIb-AMP4 and no signs of bacteria were observed in their blood and spleen samples. Also, these results confirmed the stability and higher activity of LL37-rIb-AMP4 than the single form of these proteins.

Conclusion: Considering the antimicrobial potential of the produced proteins, it seems that the recombinant LL37-rIb-AMP4 protein could be considered and used as a stable and active antimicrobial drug in future studies.

Keywords

Subjects


1. Xuan J, Feng W, Wang J, et al. Antimicrobial peptides for combating drug-resistant bacterial infections. Drug Resist Updat. 2023; 68:100954.
2. Stefanucci A, Mosquera J, Vázquez E, Mascareñas JL, Novellino E, Mollica A. Synthesis, characterization, and DNA binding profile of a macrocyclic β-sheet analogue of ARC protein. ACS Med Chem Lett. 2015;29;6(12):1220-4.
3. Xhindoli D, Pacor S, Benincasa M, Scocchi M, Gennaro R, Tossi A. The human cathelicidin LL-37--A pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta. 2016;1858(3):546-566.
4. Flórez-Castillo JM, Ropero-Vega JL, Perullini M, & Jobbágy M. Biopolymeric pellets of polyvinyl alcohol and alginate for the encapsulation of Ib-M6 peptide and its antimicrobial activity against Escherichia coli. Heliyon 2019; 5: e01872.
5. Huan Y, Kong Q, Mou H, Yi H. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front Microbiol. 2020; 11:582779.
6. Sadoogh Abbasian S, Ghaznavi-Rad E, Akbari N, Zolfaghari MR, Pakzad I, Abtahi H. Overexpression and enzymatic assessment of antigenic fragments of hyaluronidase recombinant protein from Streptococcus pyogenes . Jundishapur J Microbiol. 2015;8(1):e13653.
7. Sadoogh Abbasian S, Soufian S, Ghaznavi-Rad E, Abtahi H. High level activity of recombinant lysostaphin after computer simulation and additive-based refolding. Int J Pept Res Ther. 2019;25:1241–9.
8. Mahmoudi S, Abtahi H, Bahador A, Mosayebi G, Salmanian AH. Production of recombinant streptokinase in E. coli and reactivity with immunized mice. Pak J Biol Sci. 2010;13(8):380-384.
9. Farjadi V, Abtahi H, Zolfaghari M R, Soufian S, Hasanzadeh L. Expression, Purification and Evaluation of Antigenicity of CagA Antigenic Fragment of Helicobacter pylori. Jundishapur J Microbiol. 2013;6(9):e7367.
10. Fahimirad S, Razavi SH, Abtahi H, Alizadeh H, Ghorbanpour M. Recombinant production and antimicrobial assessment of beta casein-IbAMP 4 as a novel antimicrobial polymeric protein and its synergistic effects with thymol. Int J Pept Res Ther. 2018;24:213-22.
11. Sadoogh Abbasian S, Abtahi H, Zolfaghari MR, Soufian S and Ghaznavi-Rad E. Cloning, expression,purification and antigenic evaluation of hyaluronidase antigenic fragments recombinant protein of streptococcus pyogenes . Afr J Biotechnol 2012; 11:2376- 2380.
12. Didevara E, Sadoogh Abbasian S, Sadeghi A, Abtahi H. Production of mutant streptavidin protein and investigation of its effect on the performance of streptavidin. Iran J Basic Med Sci. 2023;26(5):572-578.
13. Mirjamali NA, Soufian S, Molaee N, Abbasian SS, Abtahi H. Cloning and expression of the enzymatic region of streptococcal hyaluronidase. Iran J Basic Med Sci. 2014;17(9):667–72.
14. Khaki M, Ganji A, Abtahi H, Mosayebi G, Baazm M, Sadoogh Abbasian S, et al. Computer simulation and additive-based refolding process of cysteine-rich proteins: VEGF-A as a model. Int J Pept Res Ther. 2018;24:555-62.
15. Clinical and Laboratory Standards Institute. M07-A10: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.
156. Fahimirad S, Abtahi H, Razavi SH, Alizadeh H, Ghorbanpour M. Production of recombinant antimicrobial polymeric protein beta casein-E 50-52 and its antimicrobial synergistic effects assessment with thymol. Molecules. 2017;22(6):822.
17.Zarei-Mehrvarz E, Fahimirad S, Ghaznavi-Rad E, Abbasian SS, Abtahi H. The LL-37 antimicrobial peptide as a treatment for systematic infection of Acinetobacter baumannii in a mouse model. Protein Pept Lett. 2023;30(1):44-53.
18. Fahimirad S, Ghaznavi-Rad E, Abtahi H, Sarlak N. Antimicrobial activity, stability, and wound healing performances of chitosan nanoparticles loaded recombinant LL37 antimicrobial peptide. Int J Pept Res Ther. 2021;27(4):2505-15.
19. Wang M, Liang C, Hu H, Zhou L, Xu B, Wang X, et al. Intraperitoneal injection (IP), intravenous injection (IV), or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis. Sci Rep. 2016;6(1):30696.
20. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens. 2021;12;10(10):1310.
21. Mba IE, Nweze EI. Antimicrobial Peptides Therapy: An Emerging Alternative for Treating Drug-Resistant Bacteria. Yale J Biol Med. 2022 ; 22;95(4):445-463.
22. Mukhopadhyay S, Bharath Prasad AS, Mehta CH, Nayak UY. Antimicrobial peptide polymers: No escape to ESKAPE pathogens-A review. World J Microbiol Biotechnol. 2020;36(9):1-4.
23. Sadelaji S, Ghaznavi-Rad E, Sadoogh Abbasian S, Fahimirad S, Abtahi H. Ib-AMP4 antimicrobial peptide as a treatment for skin and systematic infection of methicillin-resistant Staphylococcus aureus (MRSA). Iran J Basic Med Sci. 2022;25(2):232-8.
24. Fan X, Reichling J, Wink M. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria. Pharmazie. 2013;68(7):628-30.
25. Fan X, Schäfer H, Reichling J, Wink M. Bactericidal properties of the antimicrobial peptide Ib-AMP4 from Impatiens balsamina produced as a recombinant fusion-protein in Escherichia coli. Biotechnol J. 2013;8(10):1213-20.
26. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutropHils. Antimicrob Agents Chemother. 1998;42(9):2206-14.
27. Sun Y, Shang D. Inhibitory Effects of Antimicrobial Peptides on Lipopolysaccharide-Induced Inflammation. Mediators Inflamm. 2015; 2015:167572.